Myrislignan ameliorates the progression of osteoarthritis: An in vitro and in vivo study
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112887 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Liang Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, The Fourth Affiliated Hospital of Soochow University, Suzhou 215028, Jiangsu, China. Hauptthemen laut MEDLINE: Osteoarthritis, Chondrocytes, Interleukin-1beta, Rats, Sprague-Dawley. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Government of Jiangsu Province.
Abstract (Originalsprache)
Osteoarthritis (OA) is a prevalent disease of the musculoskeletal system that causes functional deterioration and diminished quality of life. Myrislignan (MRL) has a wide range of pharmacological characteristics, including an anti-inflammatory ability. Although inflammation is a major cause of OA, the role of MRL in OA treatment is still not well-understood. In this study, we analyze the anti-inflammatory and anti-ECM degradation effects of MRL both in vivo and in vitro. Rat primary chondrocytes were treated with interleukin-1β (IL-1β) to simulate inflammatory environmental conditions and OA in vitro. The in vivo OA rat model was established by anterior cruciate ligament transection (ACLT) on rat. Our investigation discovered that MRL lowers the IL-1β-activated tumor necrosis factor-α (TNF-α), cyclooxygenase-2 (COX2) and inducible nitric-oxide synthase (iNOS) expression in chondrocytes. Moreover, MRL effectively alleviates IL-1β-induced extracellular matrix (ECM) degradation and promotes ECM synthesis in chondrocytes by upregulating the mRNA level expression of collagen-II and aggrecan (ACAN), downregulating the expression of matrix metalloproteinases-3,-13 (MMP-3, MMP-13), and a disintegrin and metalloproteinase with thrombospondin motifs-5 (ADAMTS-5). Gene expression profiles of different groups identified DEGs that were mainly enriched in functions associated with NF-κB signaling pathway, and other highly enriched in functions related to TNF, IL-17, Rheumatoid arthritis and cytokine-cytokine receptor signaling pathways. Venn interaction of DEGs from the abovementioned five pathways showed that Nfkbia, Il1b, Il6, Nfkb1, Ccl2, Mmp3 were highly enriched DEGs. In addition, our research revealed that MRL suppresses NF-κB and modulates the Nrf2/HO-1/JNK signaling pathway activated by IL-1β in chondrocytes. In vivo research shows that MRL slows the progression of OA in rats. Our findings imply that MRL might be a viable OA therapeutic choice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics, The Fourth Affiliated Hospital of Soochow University, Suzhou 215028, Jiangsu, China.
- Institute of Clinical Medicine Research, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou 215153, Jiangsu, China.
- Department of Respiratory Medicine, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou 215153, Jiangsu, China. Electronic address: greentree66611@sina.com.
- Center of Translational Medicine and Clinical Laboratory, The Fourth Affiliated Hospital of Soochow University, Suzhou 215028, Jiangsu, China. Electronic address: rzzhao1@126.com.
Förderung
- National Natural Science Foundation of China
- Government of Jiangsu Province
Zitieren
APA
Wang, L., Fu, X., Xia, T., Yang, Z., & Zhao, R. (2024). Myrislignan ameliorates the progression of osteoarthritis: An in vitro and in vivo study. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112887
Vancouver
Wang L, Fu X, Xia T, Yang Z, Zhao R. Myrislignan ameliorates the progression of osteoarthritis: An in vitro and in vivo study. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112887
BibTeX
@article{Wang2024,
author = {Wang, Liang and Fu, Xuejie and Xia, Tingting and Yang, Zhao and Zhao, Runze},
title = {Myrislignan ameliorates the progression of osteoarthritis: An in vitro and in vivo study},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112887}
}
EUVIMED